[
    [
        {
            "time": "",
            "original_text": "医药生物行业双周报",
            "features": {
                "keywords": [
                    "医药",
                    "生物",
                    "双周报"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业双周报",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 4,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "张坤“踩雷”教育股！董承非、谢治宇等多个产品排名垫底",
            "features": {
                "keywords": [
                    "张坤",
                    "踩雷",
                    "教育股",
                    "董承非",
                    "谢治宇"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "教育"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "张坤“踩雷”教育股！董承非、谢治宇等多个产品排名垫底",
                "Correlation": 3,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药行业2021年半年报业绩前瞻：CXO、生物制品、创新器械、医疗服务有望持续高增长",
            "features": {
                "keywords": [
                    "医药",
                    "2021",
                    "半年报",
                    "CXO",
                    "生物制品",
                    "创新器械",
                    "医疗服务",
                    "高增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CXO",
                    "生物制品",
                    "创新器械",
                    "医疗服务"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药行业2021年半年报业绩前瞻：CXO、生物制品、创新器械、医疗服务有望持续高增长",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]